About Gilead Sciences, Inc.
https://www.gilead.comGilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
CEO
Daniel P. O'Day
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2013-01-28 | Forward | 2:1 |
| 2007-06-25 | Forward | 2:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 1,157
Ratings Snapshot
Rating : A-
Most Recent Analyst Grades
Needham
Buy
Truist Securities
Buy
TD Cowen
Buy
Citigroup
Buy
B of A Securities
Buy
Deutsche Bank
Buy
Grade Summary
Showing Top 6 of 18
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:120.63M
Value:$14.97B
VANGUARD GROUP INC
Shares:118.98M
Value:$14.76B
BLACKROCK, INC.
Shares:116.28M
Value:$14.43B
Summary
Showing Top 3 of 2,781
About Gilead Sciences, Inc.
https://www.gilead.comGilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $7.77B ▲ | $2.87B ▼ | $3.05B ▲ | 39.28% ▲ | $2.46 ▲ | $4.58B ▲ |
| Q2-2025 | $7.08B ▲ | $3.11B ▲ | $1.96B ▲ | 27.68% ▲ | $1.57 ▲ | $3.37B ▲ |
| Q1-2025 | $6.67B ▼ | $2.89B ▼ | $1.31B ▼ | 19.72% ▼ | $1.06 ▼ | $2.6B ▼ |
| Q4-2024 | $7.57B ▲ | $3.54B ▼ | $1.78B ▲ | 23.56% ▲ | $1.43 ▲ | $3.11B ▲ |
| Q3-2024 | $7.54B | $5.08B | $1.25B | 16.61% | $1 | $1.88B |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $7.35B ▲ | $58.53B ▲ | $37.08B ▲ | $21.54B ▲ |
| Q2-2025 | $5.21B ▼ | $55.72B ▼ | $36.13B ▼ | $19.68B ▲ |
| Q1-2025 | $7.93B ▼ | $56.43B ▼ | $37.36B ▼ | $19.16B ▼ |
| Q4-2024 | $11.57B ▲ | $58.99B ▲ | $39.75B ▲ | $19.33B ▲ |
| Q3-2024 | $6.7B | $54.52B | $36.13B | $18.47B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $3.05B ▲ | $4.11B ▲ | $-427M ▲ | $-1.49B ▲ | $2.19B ▲ | $3.96B ▲ |
| Q2-2025 | $1.96B ▲ | $827M ▼ | $-2.12B ▼ | $-1.57B ▲ | $-2.78B ▼ | $720M ▼ |
| Q1-2025 | $1.31B ▼ | $1.76B ▼ | $-415M ▼ | $-3.43B ▼ | $-2.06B ▼ | $1.65B ▼ |
| Q4-2024 | $1.78B ▲ | $2.98B ▼ | $-225M ▲ | $2.26B ▲ | $4.95B ▲ | $2.83B ▼ |
| Q3-2024 | $1.25B | $4.31B | $-710M | $-1.38B | $2.27B | $4.17B |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Cell Therapy Products Total Cell Therapy Product Sales | $450.00M ▲ | $460.00M ▲ | $580.00M ▲ | $520.00M ▼ |
 Liver Disease | $0 ▲ | $760.00M ▲ | $800.00M ▲ | $0 ▼ |
 Other Products Total Other product sales | $460.00M ▲ | $210.00M ▼ | $200.00M ▼ | $180.00M ▼ |
 Products Other HIV | $10.20Bn ▲ | $4.59Bn ▼ | $5.09Bn ▲ | $5.28Bn ▲ |
 Trodelvy | $670.00M ▲ | $290.00M ▼ | $360.00M ▲ | $360.00M ▲ |
 Veklury | $550.00M ▲ | $300.00M ▼ | $120.00M ▼ | $280.00M ▲ |
Revenue by Geography
| Region | Q4-2024 | Q2-2025 | Q3-2025 | Q1-2025 |
|---|---|---|---|---|
 Europe | $1.18Bn ▲ | $1.19Bn ▲ | $1.55Bn ▲ | $1.08Bn ▼ |
 Other International | $830.00M ▲ | $840.00M ▲ | $930.00M ▲ | $920.00M ▼ |
 UNITED STATES | $5.57Bn ▲ | $5.27Bn ▼ | $5.28Bn ▲ | $4.67Bn ▼ |
CEO
Daniel P. O'Day
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2013-01-28 | Forward | 2:1 |
| 2007-06-25 | Forward | 2:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 1,157
Ratings Snapshot
Rating : A-
Most Recent Analyst Grades
Needham
Buy
Truist Securities
Buy
TD Cowen
Buy
Citigroup
Buy
B of A Securities
Buy
Deutsche Bank
Buy
Grade Summary
Showing Top 6 of 18
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:120.63M
Value:$14.97B
VANGUARD GROUP INC
Shares:118.98M
Value:$14.76B
BLACKROCK, INC.
Shares:116.28M
Value:$14.43B
Summary
Showing Top 3 of 2,781